ESR1 gene mutation testing (plasma, liquid biopsy)
- Hormone-positive HER2-negative metastatic breast cancer
- Progression on aromatase inhibitor therapy
- Selection of therapy with elisistrant, fulvestrant, and other selective estrogen receptor modulators
- Monitoring of tumour mutation profile when biopsy is not possible